Behavioral Health VCs See Promise in AI-Powered Precision Care

Behavioral Health VCs See Promise in AI-Powered Precision Care

In the Age of AI and Behavioral Health Apps: Investor Perspectives

In the world of AI and shiny mental health apps, venture capital investors are looking for more than just a compelling product. They seek scalable models ready to generate revenue. This means demonstrating a strong product-market fit and the ability to reach customers efficiently, without expending excessive capital upfront.

As Anna Wang, vice president at GrayMatter Capital, stated during Behavioral Health Business’ INVEST event, “That demand is big enough and easy enough to capture and reach without spending a ton of capital up front is what we’d like to see.” GrayMatter Capital is a venture firm specializing in behavioral health investments, backing companies like Blackbird Health, Coral Care, Era, FamilyWell, firsthand, Flourish, and Manatee.

Wang noted that while she would still consider a pre-seed startup in the concept phase with a strong business case and team, a scalable model is essential. One way to showcase steady growth is by establishing in-network agreements with payers.

“While there are many companies approaching us with apps and excellent consumer-facing products,” Wang continued, “we’ve found that their go-to-market strategies can be challenging, especially at scale, with high unit economics.”

In fact, some investors are turning away from certain behavioral health products due to inadequate reimbursement pathways. Digital therapeutics, for instance, have faced challenges as an industry, with pioneers like Pear Therapeutics and Akili selling off parts, partly due to a lack of a clear reimbursement model.

“We haven’t seen enough progress regarding reimbursement,” said Shivan Bhavnani, partner at Evio and founder of GIMBHI. Evio, an investment firm with a portfolio including Calm, BetterUp, Grow Therapy, Luna, and Sway Health, is not actively seeking investments in areas lacking a clear reimbursement model.

Despite potential setbacks, investors see promise in tools that can aid providers in choosing treatments and demonstrating value. AI-powered diagnostics are a particularly hot topic for Bhavnani, who believes they can transform care in the future.

“When you step back and look at behavioral health,” Bhavnani explained, “there’s always been a question about whether our diagnostic categories truly map to biological entities. I think a multimodal AI guide can facilitate precision treatment, eliminating trial and error in psychiatry.” He gave the example of the applied behavior analysis (ABA) space, where clinics often prescribe 25 to 35 hours, but a precision diagnostic could help right-size treatment.

Furthermore, precision psychiatry and precision medicine could enable the identification of the right novel treatment. Wang noted that this could give payers more confidence in more expensive treatments, such as TMS, as they would understand the patient’s likelihood of remission with such treatment.

Leave a Reply

All Rights Reserved. Copyright © AddictionNewsHub.com 2025 AddictionNewsHub.com is not a medical, healthcare or therapeutic services provider and no medical, psychiatric, psychological or physical treatment or advice is being provided by AddictionNewsHub.com. If you are facing a medical emergency or considering suicide or self harm, please call 911 immediately.